NRx Pharma Q1 FY26 net loss narrows to $1.43 million; revenue turns to $1.07 million

NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc.

NRXP

0.00
  • NRX Pharmaceuticals posted a net loss of $1.43 million for quarter ended March 31, 2026, narrowing from a net loss of $5.51 million a year earlier.
  • Revenue totaled $1.07 million, compared with no revenue a year earlier, reflecting patient services from Dura following its September 2025 acquisition.
  • Operating loss widened to $4.74 million as total operating expense climbed to $5.81 million, led by selling, general and administrative costs of $3.81 million.
  • Cash fell to $6.71 million at quarter-end from $7.8 million at Dec. 31, 2025, while net cash used in operating activities increased to $4.3 million from $3.48 million.
  • NRX said KETAFREE and NRX-100 manufacturing site inspection was reclassified to VAI status, while FDA permission was granted to proceed with enrollment in the MIND1 trial evaluating NRX-101 with robotic-assisted TMS.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-017397), on May 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.